mTOR kinase inhibitor sensitizes T-cell lymphoblastic leukemia for chemotherapy-induced DNA damage via suppressing FANCD2 expression

Leukemia. 2014 Jan;28(1):203-6. doi: 10.1038/leu.2013.215. Epub 2013 Jul 15.
No abstract available

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antineoplastic Agents / therapeutic use*
  • DNA Damage*
  • Fanconi Anemia Complementation Group D2 Protein / genetics
  • Fanconi Anemia Complementation Group D2 Protein / metabolism*
  • Humans
  • Leukemia, T-Cell / drug therapy
  • Leukemia, T-Cell / pathology*
  • TOR Serine-Threonine Kinases / antagonists & inhibitors*

Substances

  • Antineoplastic Agents
  • Fanconi Anemia Complementation Group D2 Protein
  • MTOR protein, human
  • TOR Serine-Threonine Kinases